Abstract:Copper plays critical roles as a metal active site cofactor and metalloallosteric signal for enzymes involved in cell proliferation and metabolism, making it an attractive target for cancer therapy. In this study, we investigated the efficacy of polydopamine nanoparticles (PDA NPs), classically applied for metal removal from water, as a therapeutic strategy for depleting intracellular labile copper pools in triple negative breast cancer models through the metal-chelating groups present on PDA surface. By using the activity-based sensing probe FCP-1, we could track the PDA-induced labile copper depletion while leaving total copper levels unchanged, and link it to the selective MDA-MB-231 cell death. Further mechanistic investigations revealed that PDA NPs increased reactive oxygen species (ROS) levels, potentially through the inactivation of superoxide dismutase 1 (SOD1), a copper-dependent antioxidant enzyme. Additionally, PDA NPs were found to interact with the mitochondrial membrane, resulting in an increase in mitochondrial membrane potential, which may contribute to enhanced ROS production. We employed an in vivo tumor model to validate the therapeutic efficacy of PDA NPs. Remarkably, in the absence of any additional treatment, the presence of PDA NPs alone led to a significant reduction in tumor volume by a factor of 1.66 after 22 days of tumor growth. Our findings highlight the potential of PDA NPs as a promising therapeutic approach for selectively targeting cancer by modulating copper levels and inducing oxidative stress, leading to tumor growth inhibition as shown in these triple negative breast cancer models.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to target abnormal copper metabolism (cuproplasia) in cancer through nanomedicine methods. Specifically, polydopamine nanoparticles (PDA NPs) are used to chelate intracellular labile copper, thereby inhibiting tumor growth. The research mainly focuses on the triple - negative breast cancer (TNBC) model, which is a particularly aggressive type of breast cancer lacking effective treatment methods. Through the selective copper - chelating effect of PDA NPs, the researchers hope to achieve selective killing of TNBC cells without affecting the functions of normal cells. ### Main research contents: 1. **Synthesis and characterization of PDA NPs**: The researchers first synthesized PDA NPs and analyzed their morphology and particle size distribution through transmission electron microscopy (TEM) and dynamic light scattering (DLS), confirming the uniformity and stability of the NPs. 2. **Copper - chelating ability**: The high - efficiency copper - chelating ability of PDA NPs was verified by experiments, especially under physiological conditions (pH 7.4). 3. **Cytotoxicity assessment**: The cytotoxicity of PDA NPs to different breast cell lines (including the TNBC cell line MDA - MB - 231 and the normal breast cell line MCF - 10A) was studied. The results showed that PDA NPs had significant cytotoxicity to MDA - MB - 231 cells, while having a relatively small impact on MCF - 10A cells. 4. **Copper - chelating mechanism**: The change of intracellular labile copper after PDA NPs treatment was detected using the active group probe FCP - 1. It was found that PDA NPs could effectively reduce the level of intracellular labile copper in MDA - MB - 231 cells without affecting the total copper content. 5. **Oxidative stress and metabolic changes**: Further research found that PDA NPs treatment led to an increase in the level of reactive oxygen species (ROS) in MDA - MB - 231 cells, which might be related to the decrease in superoxide dismutase 1 (SOD1) activity. In addition, PDA NPs also affected the mitochondrial membrane potential (ΔΨ) and increased the mitochondrial respiration rate, thereby further promoting the generation of ROS. 6. **In vivo experiments**: The anti - tumor effect of PDA NPs was verified in a mouse model. The results showed that PDA NPs could significantly inhibit the growth of MDA - MB - 231 tumors, and no obvious toxic side effects were observed. ### Conclusion: PDA NPs selectively kill TNBC cells by chelating intracellular labile copper, inducing oxidative stress and metabolic changes. This strategy provides new ideas for the development of new therapies for TNBC, especially in the case of limited existing treatment methods.

A nanomedicine approach to targeting cuproplasia in cancer: Labile copper sequestration using polydopamine nanoparticles blocks tumor growth in vivo through altering metabolism and redox homeostasis.

Nanomedicine Targeting Cuproplasia in Cancer: Labile Copper Sequestration Using Polydopamine Particles Blocks Tumor Growth In Vivo through Altering Metabolism and Redox Homeostasis

Copper Deposition in Polydopamine Nanostructure to Promote Cuproptosis by Catalytically Inhibiting Copper Exporters of Tumor Cells for Cancer Immunotherapy

Smart Design of a Therapeutic Nanoplatform for Mitochondria-Targeted Copper-Depletion Therapy Combined with Chemotherapy.

Copper-mediated Chemodynamic Therapy with Ultra-Low Copper Consumption by Doping Cupric Ion on Cross-Linked (R)-(+)-lipoic Acid Nanoparticles

Detention of copper by sulfur nanoparticles inhibits the proliferation of A375 malignant melanoma and MCF-7 breast cancer cells

Regenerating Chemotherapeutics through Copper-Based Nanomedicine: Disrupting Protein Homeostasis for Enhanced Tumor Therapy

In Situ Sacrificial Growth of Metastable Copper-Enriched Nanomedicine for Cuproptosis-Based Synergistic Cancer Therapy

Copper‐Based Composites Nanoparticles Improve Triple‐Negative Breast Cancer Treatment with Induction of Apoptosis‐Cuproptosis and Immune Activation

Biomimetic copper-doped polypyrrole nanoparticles induce glutamine metabolism inhibition to enhance breast cancer cuproptosis and immunotherapy

A Paclitaxel Prodrug with Copper Depletion for Combined Therapy toward Triple-Negative Breast Cancer

Cuproptosis and Serine Metabolism Blockade Triggered by Copper‐Based Prussian Blue Nanomedicine for Enhanced Tumor Therapy

Copper depletion-induced tumor cuproptosis

Responsively Aggregatable Nanochelator-Mediated Antiangiogenesis to Enhance Interventional Therapies for Liver Cancer

Cell-penetrating peptide-conjugated copper complexes for redox-mediated anticancer therapy

Redox homeostasis disruptors enhanced cuproptosis effect for synergistic photothermal/chemodynamic therapy

P-selectin-targeted Polyguluronate Sulfate-Copper Peroxide Nanomicelles for Chemodynamic Therapy of Breast Cancer

Three Birds with One Stone: Copper Ions Assisted Synergistic Cuproptosis/Chemodynamic/Photothermal Therapy by a Three-Pronged Approach

Polyvalent Aptamer Nanodrug Conjugates Enable Efficient Tumor Cuproptosis Therapy Through Copper Overload and Glutathione Depletion

Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD‐L1 for Enhanced Cancer Immunotherapy

Copper-Based Nanomedicines for Cuproptosis-Mediated Effective Cancer Treatment